Poseida Therapeutics

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Aug. 12, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the second quarter ended June 30, 2021. Poseida Therapeutics today announced program updates and financial results for the second quarter ended June 30, 2021.

Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021

SAN DIEGO, July 26, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of biotechnology industry veteran Cynthia Collins to its Board of Directors, effective July 23, 2021. "We are excited to welcome Cindy to Poseida's Board of Directors," said Eric Ostertag, M.D.

Poseida Therapeutics Appoints Cynthia Collins to Board of Directors

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held virtually via live webcast on Wednesday, June 16, 2021 at 1:00pm PT.  Stockholders of record at the close of business on April 20, 2021, are entitled to vote in the Annual Meeting.

Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021. "We are encouraged by our continued progress in first quarter of 2021, building on the accomplishments from the prior year as we moved multiple programs forward to important inflection points, including our ongoing P-BCMA-101 and P-PSMA-101 CAR-T programs, on which we plan to provide further clinical updates later in the year," said Eric Ostertag, M.D.

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure,  today will give multiple oral and poster presentations at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting being held May 11-14, 2021. The Company's oral presentation will highlight new data demonstrating the potential of its proprietary piggyBac DNA Delivery System for the treatment of genetic liver disorders in children and infants.

Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting

SAN DIEGO, May 6, 2021 /PRNewswire/ --  Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of three new members to its Scientific Advisory Board (SAB). These internationally recognized researchers will join Dr. Carl June, the chairman of Poseida's Immuno-Oncology (I/O) SAB, to advise and provide counsel on the Company's research and development efforts in CAR-T cell therapy.

Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board

SAN DIEGO, May 5, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company's CEO, Eric Ostertag, MD, PhD, will present at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 2:45pm ET. A webcast of the presentation will be available on the Investors & Media Section of the Poseida website, www.poseida.com.

Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference

SAN DIEGO, April 27, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced three data presentations to be delivered at the upcoming American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting, being held virtually May 11-14, 2021. Poseida will present the following research at the 2021 ASGCT Annual Meeting: Oral Presentation Title: Preclinical Evaluation of Combined Adeno-Associated Virus and Nanoparticle Delivery of piggyBac® Transposon System for Durable Transgene Expression in the Growing Neonatal Murine Liver Session Date/Time: Tuesday, May 11, 2021, 5:45pm - 6:00pm ET Abstract Number: 30 Poster Presentations Title: P-BCMA-ALLO1 — A Fully Allogeneic Stem Cell Memory T Cell (T SCM ) CAR-T Therapy Targeting BCMA for the Treatment of Multiple Myeloma Shows Potent Anti-Tumor Activity Session Date/Time: Tuesday, May 11, 2021, 8:00am – 10:00am ET Abstract Number: 789 Title: Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer Non-Genotoxic Stem Cell Transplant Conditioning Session Date/Time: Tuesday, May 11, 2021, 8:00am – 10:00am ET Abstract Number: 715 About Poseida Therapeutics, Inc. Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting

SAN DIEGO, March 23, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of distinguished scientist Carl June, M.D., who will serve on Poseida's Scientific Advisory Board (SAB).

Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board

PSTX is an early-stage CAR-T and gene therapy developer. Lead asset is targeting multiple myeloma and has early-stage data.

Poseida: Early Stage CAR-T And Gene Therapy Developer

SAN DIEGO, March 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the fourth quarter and full year ended December 31, 2020. "2020 was a transformative year for Poseida, as we completed our IPO and became a public company all while advancing multiple programs and substantially expanding the application of our core technologies, enabling us to engineer a portfolio of product candidates designed to overcome the limitations of current cell and gene therapeutics," said Eric Ostertag, M.D.

Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020

PRA Health Sciences

Salarius Pharmaceuticals Inc

Sunesis Pharmaceuticals

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC.

Why Sunesis, Poseida, Salarius And PRA Health Are Rallying

The biotech reported pipeline progress at its virtual R&D Day.

Why Poseida Therapeutics Stock Is Popping Today

SAN DIEGO, Dec. 5, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today reported results of an ongoing...

Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting

SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure,...

Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer

SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure,...

Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc.

Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020

LOS ANGELES--(BUSINESS WIRE)---- $PSTX #PSTX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $PSTX #PSTX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Poseida Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $GNUS #ClassAction--Shareholder rights law firm Robbins LLP is investigating whether Poseida Therapeutics, Inc. (NASDAQ: PSTX) and its officers and directors violated securities laws and engaged in unlawful business practices in connection with its initial public offering ("IPO").

Robbins LLP Is Investigating the Officers and Directors of Poseida Therapeutics, Inc. (PSTX) on Behalf of Shareholders

SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc.

Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Poseida Therapeutics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Poseida Therapeutics, Inc. - PSTX

Poseida Therapeutics Inc. (NASDAQ: PSTX) stock dropped about 34.5% in the after-hours trading on Monday, after a patient died in a prostate cancer drug trial, according to a filing the company made with the United States Securities and Exchange Commission.

Poseida Shares Tank 34.5% As Prostate Cancer Drug Trial Halted After Patient's Death

Poseida Therapeutics Inc. shares dropped in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patient death.

Poseida stock drops more than 30% as prostate cancer drug trial halted after patient dies

Poseida Therapeutics Inc. PSTX, -0.76% shares were halted in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patient death.

News for Poseida Therapeutics Stock (PSTX)